Q4 2025 Biostem Technologies Inc Earnings Call Transcript
Key Points
- BioStem Technologies Inc (BSEM) has diversified its business by acquiring BioTissue's surgical and wound assets, expanding its presence in hospital-based settings.
- The company reported a solid fourth-quarter revenue of $10.1 million, driven by sales to physician office customers.
- BioStem's clinical trials, including the DFU study, demonstrated the superiority of its bio retained process product over the standard of care, positioning the company well in the market.
- The acquisition of BioTissue's assets has expanded BioStem's product portfolio with well-recognized allograft brands, Neox and Clarix, enhancing its capabilities across multiple tissue formats.
- BioStem has entered into a manufacturing and supply agreement with BioTissue, ensuring continuity of supply and quality during the integration period, with plans to bring manufacturing in-house for significant gross margin expansion.
- The company anticipates a significant decline in physician office revenue for 2026 due to CMS reimbursement changes impacting practice economics.
- Operating expenses increased to $17.3 million in the fourth quarter, driven by potential uncollectible accounts receivable and increased legal costs.
- BioStem is currently a consumer of cash, with expectations to continue consuming cash throughout 2026, potentially impacting its financial stability.
- The physician office business experienced a significant drop in Q1 2026 due to CMS reimbursement changes, affecting overall revenue.
- The company faces challenges in the physician office market, which is down across the segment, with a pullback on the use of skin substitutes as the market adjusts to new payment environments.
Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biostem Technologies fourth-quarter and full year 2025 earnings conference call. (Operator Instructions)
And I would now like to turn the conference over to Trip Taylor with Investor Relations. You may begin.
Good afternoon, everyone, and thank you for joining our conference call to discuss Biostem's fourth-quarter 2025 financial results and corporate highlights. Leading the call today will be Jason Matuszewski, the company's Chairman and Chief Executive Officer; Barry Hassett, the company's Chief Commercial Officer; and Brandon Poe, the company's Chief Financial Officer.
Before we begin, I'd like to remind everyone that our remarks may contain forward-looking statements based on management's current expectations. These involve inherent risks and uncertainties that could cause actual results to differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
